Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0604 • ACR Convergence 2023
Is Belimumab Dose Optimization Possible in Patients with Systemic Lupus Erythematosus?: Analysis of This Therapeutic Strategy in a Large Multicenter Cohort of Patients from Spanish Rheumatology Departments
Irene Altabas Gonzalez¹, Jose-Maria Pego-Reigosa², CORAL Mourino Rodriguez³, Norman Jiménez⁴, Andrea Hernández-Martín⁵, Judit Font⁶, Ivette Casafont-Sole⁷, Jose Andres Roman Ivorra⁸, Marta De la Rubia Navarro⁹, Maria Galindo¹⁰, TAREK CARLOS SALMAN MONTE¹¹, Javier Narvaez¹², Paola Vidal-Montal¹³, Maria J. García-Villanueva¹⁴, Sandra Garrote Corral¹⁴, María Ángeles Blázquez Cañamero¹⁵, carlos Marras Fernández-Cid¹⁶, María Piqueras García¹⁷, JULIA MARTINEZ BARRIO¹⁸, Marina Sánchez-Lucas¹⁹, Josefina Cortés Hernández²⁰, Eleonora Penzo²¹, Jaime Calvo Alén²², Juan Ramón de Dios Jiménez de Aberásturi²³, Belén Álvarez Rodríguez²⁴, Margarida Rocha²⁵, Eva Tomero Muriel²⁶, Raúl Menor-Almagro²⁷, Myriam Gandía Martínez²⁸, Jose A Gomez-Puerta²⁹, Beatriz Frade³⁰, Consuelo Ramos-Giráldez³¹, Carmen Trapero Pérez³², MARIA ELVIRA DIEZ ALVAREZ³³, Clara Moriano Morales³³, Alejandro Muñoz³⁴ and Iñigo Rúa-Figueroa³⁵, ¹Complejo Hospitalario Universitario de Vigo, IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ²Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ³Complejo Hospitalario Universitario de Vigo. IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ⁴IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, ⁵Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain, ⁶Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁷Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁸Hospital Universitari i Politècnic la Fe, Valencia, Spain, ⁹Hospital Universitario y Politécnico de la Fe, Valencia, Spain, ¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ¹²Hospital Universitario de Bellvitge, Barcelona, Spain, ¹³Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁴Hospital Ramón y Cajal, Madrid, Spain, ¹⁵Rheumatology Department Hospital Ramon y Cajal, Madrid, Spain, ¹⁶Rheumatology, Hospital Virgen Arrixaca, Murcia, Spain, ¹⁷Hospital Virgen de la Arrixaca de Murcia, Murcia, Spain, ¹⁸Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ¹⁹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²⁰Lupus Unit, Rheumatology Department, Vall d’Hebron Hospitals, Barcelona, Spain, ²¹Hospital Universitario Valle d´ Hebrón, Barcelona, Spain, ²²Hospital Universitario Araba, Vitoria, Spain, ²³Hospital Universitario Araba, Álava, Spain, ²⁴Hospital de Araba, Vitoria, Spain, ²⁵Osakidetza, Bilbo, Spain, ²⁶Rheumatology, Hospital La Princesa, Madrid, Spain, ²⁷Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ²⁸Hospital de Jerez, Jerez, Spain, ²⁹Department of Rheumatology, Hospital Clinic of Barcelona, Barcelona, Spain, ³⁰Hospital Clinic, Barcelona, Spain, ³¹Rheumatology Department Hospital Universitario Virgen de Valme, Sevilla, Spain, ³²Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain, ³³Rheumatology, Hospital Universitario de León, León, Spain, ³⁴Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ³⁵Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain
Background/Purpose: Belimumab (BLM) is an IgG-1l anti-BAFF monoclonal antibody effective in patients with systemic lupus erythematosus (SLE), being used increasingly. However, there are no published…
Abstract Number: 0826 • ACR Convergence 2023
Development of a Decision Aid for Clinical Trial Participation in Systemic Lupus Erythematosus
Leila Khalili¹, Rita Kukafka², Laura Geraldino-Pardilla¹, Nancyanne Schmidt¹, Sean Inzerillo¹, Julia Weiner¹, Wei Tang¹ and Anca Askanase³, ¹Division of Rheumatology, Columbia University Irving Medical Center, New York, NY, ²Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, ³Columbia University Medical Center, New York, NY
Background/Purpose: Standard of care therapy for SLE relies heavily on broad-spectrum immune suppressants. Therapeutic drug development is critical to the approval of targeted therapies; however,…
Abstract Number: 0897 • ACR Convergence 2023
Steroid-sparing Effects of Afimetoran (BMS-986256), an Equipotent Toll-like Receptor (TLR)7 and TLR8 Antagonist, in a Lupus Mouse Model
Shailesh Dudhgaonkar¹, Puneet Chopra², Anjuman Rudra², Siva Subramani², Sourabha Palachandra², Nikita Bhatt², Veeresh Pabbala², Sourabh Ranade², Durga Siva Prasad Ega², Alaric Dyckman³ and Qihong Zhao³, ¹Bristol Myers Squibb, Bangalore, India, ²Biocon Bristol Myers Squibb Research Center, Bangalore, India, ³Bristol Myers Squibb, Lawrenceville, NJ
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with extensive phenotypic heterogeneity due to the underlying molecular diversity of dysregulated pathways. Patients with…
Abstract Number: 0916 • ACR Convergence 2023
Upregulation of the M-CSF Receptor on Non-Classical Monocytes from SLE Patients as an Indicator for Premature Monocyte Aging
Markus Zeisbrich¹, Stephanie Finzel², Nils Venhoff¹ and Reinhard Voll¹, ¹University Medical Center Freiburg, Freiburg, Germany, ²Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany
Background/Purpose: Circulating monocytes are divided into three subsets: classical, intermediate, and non-classical monocytes. Monocytes egress from the bone marrow as classical monocytes and develop into…
Abstract Number: 1043 • ACR Convergence 2023
Comparison of Optical and Ultrasound Imaging in Lupus Arthritis
Wei Tang¹, Alessandro Marone², Leila Khalili¹, Xin Wang¹, Shane Murray¹, Sean Inzerillo¹, Moegammad Bardien², Vedant Gaikwad², Stephen Kim², Laura Geraldino-Pardilla¹, Andreas Hielscher² and Anca Askanase³, ¹Division of Rheumatology, Columbia University Irving Medical Center, New York, NY, ²Department of Biomedical Engineering, Tandon School of Engineering, New York University, Brooklyn, NY, ³Columbia University Medical Center, New York, NY
Background/Purpose: Almost all patients with SLE experience joint problems and arthritis, 12% suffer permanent joint damage. The wide variability in SLE arthritis and the limitations…
Abstract Number: 1238 • ACR Convergence 2023
Prevalence of Celiac Disease Among Children and Adolescents with Systemic Lupus Erythematosus (SLE)
Oscar Mwizerwa¹, Andrea Knight², Daniela Dominguez², Deborah Levy², Holly Convery², Kendal Thompson², Nicholas Gold², Catherine M Walsh² and Linda Hiraki², ¹University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) and celiac disease (CD) are autoimmune diseases characterized by the presence of specific autoantibodies. We aimed to investigate the prevalence…
Abstract Number: 1442 • ACR Convergence 2023
Incident Vascular Events in Danish Nationwide Cohort of Patients with Newly Diagnosed Systemic Lupus Erythematosus
Renata Baronaite Hansen¹, Julia Simard², Mikkel Faurschou¹ and Søren Jacobsen³, ¹Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ²Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ³Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Awareness of comorbidity in patients with SLE is increasing. Most studies to date have described comorbidity burden in prevalent SLE. We estimated the incidence…
Abstract Number: 1459 • ACR Convergence 2023
Unveiling the Impact of Neuropsychiatric Involvement in Systemic Lupus Erythematosus on Damage Accrual
Dionysis Nikolopoulos¹, Nursen Cetrez², Julius Lindblom² and Ioannis Parodis², ¹Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The link between neuropsychiatric involvement in systemic lupus erythematosus (NPSLE) and heightened morbidity, mortality, and organ damage, as well as detrimental impacts on health-related…
Abstract Number: 1475 • ACR Convergence 2023
Retrospective Study of Obesity on Clinical and Immunological Features in Systemic Lupus Erythematosus Using AI Software Deep 6 and EPIC Slicer Dicer
Shivani Shah¹, chandana keshavamurthy¹, Samantha Ahrens¹, Douglas Reeves¹, William Davis¹, Robert Quinet¹, Jerald Zakam¹, Samina Hayat², Teresa Leeth², Sarwat Umer³, Sulman Hasan², Maria Latsis², Xin Zhang¹ and Gitanjali Lobo⁴, ¹Ochsner Health, New Orleans, LA, ²Louisiana State University, Shreveport, LA, ³LSU Health Shreveport, Shreveport, LA, ⁴Ochsner Clinic Foundation, Baton Rouge, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by autoantibodies and systemic inflammation, affecting multiple organs especially kidney. Environmental factors, genetic predisposition,…
Abstract Number: 1493 • ACR Convergence 2023
Novel BCMA-CD19 Compound CAR-T (cCAR) Targets B Cells and Plasma Cells Achieving Immune Reset and Eliminates All Autoantibodies in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients Resulting in Long-Term, Medication-Free Remission
Yong Yuan¹, Shanzhi He¹, Wenli Zhang², Hongyu Zhang², Vincent DeStefano³, Masayuki Wada³, Kevin Pinz³, Greg Deener³, Yu Ma⁴, Min Wang¹, Fugui Li¹, Ming Hong¹, Chanjuan Zou¹, Mingxia Wang¹, Ling Ding¹, Yingwen Liang¹, Yupo Ma³ and Weijia Wang¹, ¹Zhongshan People’s Hospital, Zhongshan, China, ²Peking University Shenzhen Hospital, Shenzhen, China, ³iCell Gene Therapeutics Inc., Stony Brook, NY, ⁴iCAR Bio Therapeutics Ltd, Zhongshan, China
Background/Purpose: Evaluate cCAR safety in SLE, LN and autoimmune conditions. Determine whether a single dose eliminates autoantibodies with well tolerated long-term, medication-free remission in open…
Abstract Number: 1512 • ACR Convergence 2023
Rituximab Objective Outcome Measures Trial in SLE (ROOTS): Randomised and Rescue Therapy Outcomes from a Randomised Controlled Trial
Khaled Mahmoud, Michelle Wilson, Md Yuzaiful Md Yusof, Sarah Brown, Elizabeth Hensor and Ed Vital, University of Leeds, Leeds, United Kingdom
Background/Purpose: New medicines in SLE have not met endpoints in placebo-controlled RCTs when other evidence indicates they are effective. Reasons suggested are inclusion of patients…
Abstract Number: 1618 • ACR Convergence 2023
Intervention to Improve Medication Adherence Among Patients with SLE
Kai Sun¹, Nneka Molokwu¹, Emily Hanlen¹, Amy Corneli², Kathryn Pollak¹, Jennifer Rogers¹, Rebecca Sadun¹, Lisa Criscione-Schreiber², Jayanth Doss¹, Hayden Bosworth¹ and Megan Clowse³, ¹Duke University, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Chapel Hill, NC
Background/Purpose: Medication nonadherence is common and is associated with increased disease activity, morbidity, and mortality in SLE. To optimize medication adherence and SLE outcomes, we…
Abstract Number: 1841 • ACR Convergence 2023
Clinical Trial Perceptions Among Male Patients with Systemic Lupus Erythematosus (SLE): Georgians Organized Against Lupus (GOAL) Cohort
Hilton Mozee¹, Charmayne Dunlop-Thomas¹, Gaobin Bao¹, Kim Schofield², Jessica Williams³ and S. Sam Lim¹, ¹Emory University, Atlanta, GA, ²Georgia State Rep. HD 63, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA
Background/Purpose: Minority patients are disproportionately affected by SLE. Yet, they are underrepresented in SLE clinical trials compared to White patients. Specifically, patients that identify as…
Abstract Number: 2258 • ACR Convergence 2023
Brain Activity Patterns and Behavioural Performance in SLE Patients During a Spatial Working Memory and Sustained Attention Task
Michelle Barraclough¹, Shane McKie², Alex Kafkas², Ben Parker³, Juan Pablo Diaz Martinez⁴, Andrea Knight⁵, Kathleen Bingham¹, Jiandong Su¹, Mahta Kakvan⁶, Carolina Munoz-Grajales⁷, Carmela Tartaglia⁸, Lesley Ruttan⁹, Joan Wither¹, Dennisse Bonilla¹, Daniela Montaldi², Rebecca Elliott², Patti Katz¹⁰, Dorcas Beaton¹¹, Robin Green⁹, Ian Bruce² and Zahi Touma¹², ¹University Health Network, Toronto, ON, Canada, ²University of Manchester, Manchester, United Kingdom, ³Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁴Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶University Health Network, University of Toronto, Toronto, ON, Canada, ⁷UHN/TWH, Toronto, ON, Canada, ⁸Krembil Brain Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁹University Health Network, Toronto Rehabilitation Institute, Toronto, ON, Canada, ¹⁰University of California San Francisco, San Rafael, CA, ¹¹Institute for Work & Health, Toronto, ON, Canada, ¹²University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is a significant problem in SLE but there is a disconnect between objective and subjective CI. This makes it difficult to…
Abstract Number: 2274 • ACR Convergence 2023
Lupus Low Disease Activity State as an Attainable Target in Lupus Nephritis Associated with Reduced Risk of Relapse
Chak Kwan Cheung¹, Chak Sing Lau² and Shirley Chiu Wai Chan³, ¹Divison of Rheumatology and Clinical Immunology, Queen Mary Hospital, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, ²University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³Divison of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Lupus nephritis (LN) is a significant comorbidity affecting approximately up to 50-60% of patients with systemic lupus erythematosus (SLE). Complete renal response (CRR) and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].